Talk:DBT

From PsychonautWiki
Jump to navigation Jump to search


Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

DBT
DBT.svg
Chemical Nomenclature
Common names DBT, N,N-DBT
Substitutive name N,N-Dibutyltryptamine
Systematic name N-Butyl-N-[2-(1H-indol-3-yl)ethyl]butan-1-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.










Intramuscular
Dosage
Common 1mg/kg
Duration


DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


N,N-Dibutyltryptamine, (also known as DBT) is a obscure novel psychedelic substance of the tryptamine class. DBT is strucally related to DMT, along with other analogs such as DiPT, MPT, and MET.

DBT was investigated by Alexander Shulgin and described in his book TiHKAL ("Tryptamines I Have Known and Loved"). Here, he lists a dosage of 1mg/kg intramuscular[1], though this has been contested by other reports, saying the dosage is larger[2]. It is less active than other similar compounds such as DMT or DET[3]. Aside from this, very little is known about the dosage, effects, and safety profile of the compound.

It is highly advised to use harm reduction practices if using this substance.

Chemistry

DBT, or N,N-dibutyltryptamine, is a member of a family of organic compounds known as tryptamines. Tryptamines share a core structure consisting of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DBT contains two butyl groups (CH3−CH2−CH2−CH2−) bound to the terminal amine RN at the end of this chain. It contains no ring substitutions, making it a base tryptamine. As with the base compound, any ring substitutions of DBT have very little known of them.

Pharmacology

Little is known about the pharmacology of DBT. It has been shown to produce a head-twitch response in mice[4], meaning it is possibly psychoactive. Some have speculated that it is active orally, possibly due to the long butyl chain, as opposed to a compound such as DMT, which has a much shorter chain and is not active orally on its own.

Subjective effects

Metacogghjgjvghnition.png
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

No subjective effects of DBT have been reported in the literature, with many reports even suggesting it is only minimally psychoactive.

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.


Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Very little is known about the safety profile of DBT. Because of this, it is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

A lethal dosage of DBT has not been established, partly due to the fact that no attempts to do so have been made.

Tolerance and addiction potential

In studies on rats, minimal rewarding and reinforcing effects were found regarding DBT, as the rats did not reliably self-administer the compound. This is also the case with many other tryptamines.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

DBT is not stated as illegal in any location, but it would possibly fall under analog laws due to its similarity to controlled substances.

See also

External links

References

  1. Shulgin, Alexander; Shulgin, Ann (1997). "#2 DBT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  2. Szara, Stephen. "DMT (N,N-DIMETHYLTRYPTAMINE) AND HOMOLOGUES: CLINICAL AND PHARMACOLOGICAL CONSIDERATIONS". 
  3. https://en.wikipedia.org/wiki/Dibutyltryptamine.  Text "title-Dibutyltryptamine" ignored (help); Missing or empty |title= (help)
  4. Abiero A, Ryu IS, Botanas CJ, Custodio RJ, Sayson LV, Kim M, et al. (June 2019). "Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice". Biomolecules & Therapeutics. 28: 83–91. doi:10.4062/biomolther.2019.049. PMC 6939696Freely accessible. PMID 31230432. 
  5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.